Вход на сайт

Просмотр новости

Найдите то, что Вас интересует

FSSAI initiates legal action against Nestle India over infant nutrition products

Дата публикации: 19-09-2026 05:18:02

FSSAI has sought clarifications from Nestle India on claims relating to ‘5HMOs’ and ‘Whey Protein’

Основное содержимое страницы с новостью.

The food safety authority examined Nestle’s NAN Excella Pro Stage 1, Lactogen Pro 1, and a follow-up formula along with their promotional material available on e-commerce platforms

The food safety authority examined Nestle’s NAN Excella Pro Stage 1, Lactogen Pro 1, and a follow-up formula along with their promotional material available on e-commerce platforms | Photo Credit: Reuters

The Food Safety and Standards Authority of India (FSSAI) on Friday said it has initiated legal action against Nestle India Ltd for alleged non-compliance with food safety norms in three infant nutrition products.

According to FSSAI, it examined NAN Excella Pro Stage 1, Lactogen Pro 1, and a follow-up formula along with their promotional material available on e-commerce platforms.

In NAN Excella Pro Stage 1, the regulator flagged claims relating to "5HMOs" and "Whey Protein," while in Lactogen Pro 1, it observed a claim describing "Whey Protein" as easy to digest, the regulator said in a social media post.

FSSAI said it had sought clarifications from Nestle India on these claims.

Both the products were found to be in contravention of Regulation 4(2) of the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020, which restrict promotional claims or material aimed at increasing the saleability of infant foods, as well as Section 3 of the Infant Milk Substitutes, Feeding Bottles and Infant Foods (Regulation of Production, Supply and Distribution) Act, 1992, which bars the advertisement or promotion of such products.

Separately, a sample of a follow-up formula manufactured by Nestle India was found sub-standard for Biotin content during laboratory analysis. The sample was sent for re-analysis, and the referral laboratory also found it non-conforming with the Biotin requirement prescribed under the 2020 regulations.

In light of these findings, FSSAI has filed three separate adjudication cases against Nestle India in respect of the three products, it added.

At 1.10 p.m., shares of Nestle India were down nearly 2% at ₹1,345.45 on the BSE.

Published - September 18, 2026 02:49 pm IST

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1Supreme Court slams FSSAI for not introducing front-of-pack warning labels on packaged food products011.0714-08-2026
2FSSAI makes U-turn, revokes order against Enrica products022.515-08-2026
3Who’s watching what we eat? Inside India’s food adulteration problem08.0119-09-2026
4ФАС возбудила дело против "Сургутнефтегаза" о нарушении антимонопольного законодательства0016-02-2022
5Tasmac halts sale of 11 Enrica liquor brands in T.N. following FSSAI inspection09.1715-08-2026
6ФАС возбудила дело против Lindt из-за различий в качестве шоколада в России и Европе0025-08-2020
7"Известия": Роспотребнадзор проверит продукцию Johnson & Johnson0027-04-2023
8ФАС возбудила дело против фирмы «Фермент» из-за роста цен на бифилиз019.0922-07-2026
9ФАС возбудила дела о высоких ценах на рынке серной кислоты06.4926-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 7.83. Источник: www.thehindu.com.